Literature DB >> 9692858

Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.

D R Surman1, K R Irvine, E P Shulman, T M Allweis, S A Rosenberg, N P Restifo.   

Abstract

Lymphocytes from patients with melanoma have been used to clone melanoma associated antigens which are, for the most part, nonmutated melanocyte tissue differentiation antigens. To establish a mouse model for the use of these 'self' antigens as targets for anti-tumor immune responses, we have employed the mouse homologues of the human melanoma antigens Tyrosinase, Tyrosinase Related Protein-1 (TRP-1), gp100, and MART-1. We sought to generate antisera against these proteins for use in the construction of experimental recombinant and synthetic anti-cancer vaccines, and for use in biologic studies. Using genes cloned from the B16 mouse melanoma or from murine melanocytes, we immunized rabbits with plasmid DNAs coated onto microscopic gold beads that were then delivered using a hand-held, helium-driven 'gene gun'. This strategy enabled us to generate polyclonal rabbit sera containing antibodies that specifically recognized each antigen, as measured by immunostaining of vaccinia virus infected cells. The sera that we generated specifically for TRP-1, gp100, and MART-1 recognized extracts of the spontaneous murine melanoma, B16. The identities of the recognized proteins was confirmed by Western blot analysis. The titers and specificities of these antisera were determined using ELISA. Interestingly, serum samples generated against murine MART-1 and gp100 developed antibodies that were cross-reactive with the corresponding human homologues. Recognition of human gp100 and murine Tyrosinase appeared to be dependent upon conformational epitopes since specificity was lost upon denaturation of the antigens. These antisera may be useful in the detection, purification and characterization of the mouse homologues of recently cloned human tumor associated antigens and may enable the establishment of an animal model of the immune consequences of vaccination against 'self antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692858      PMCID: PMC1951532          DOI: 10.1016/s0022-1759(98)00036-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  29 in total

1.  Genetic immunization is a simple method for eliciting an immune response.

Authors:  D C Tang; M DeVit; S A Johnston
Journal:  Nature       Date:  1992-03-12       Impact factor: 49.962

2.  A monoclonal antibody specific for cells of the melanocyte lineage.

Authors:  C Vennegoor; P Hageman; H Van Nouhuijs; D J Ruiter; J Calafat; P J Ringens; P Rümke
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

3.  Cloning and expression of cDNA encoding mouse tyrosinase.

Authors:  S Shibahara; Y Tomita; T Sakakura; C Nager; B Chaudhuri; R Müller
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

4.  Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

Authors:  B S Chapman; R M Thayer; K A Vincent; N L Haigwood
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

5.  Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.

Authors:  A M Gown; A M Vogel; D Hoak; F Gough; M A McNutt
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

6.  Production of monoclonal antibodies by genetic immunization.

Authors:  M A Barry; M E Barry; S A Johnston
Journal:  Biotechniques       Date:  1994-04       Impact factor: 1.993

7.  Tyrosinases from two different loci are expressed by normal and by transformed melanocytes.

Authors:  M Jiménez; K Tsukamoto; V J Hearing
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

8.  Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody.

Authors:  T M Thomson; M J Mattes; L Roux; L J Old; K O Lloyd
Journal:  J Invest Dermatol       Date:  1985-08       Impact factor: 8.551

9.  Pigment production in murine melanoma cells is regulated by tyrosinase, tyrosinase-related protein 1 (TRP1), DOPAchrome tautomerase (TRP2), and a melanogenic inhibitor.

Authors:  K Kameyama; T Takemura; Y Hamada; C Sakai; S Kondoh; S Nishiyama; K Urabe; V J Hearing
Journal:  J Invest Dermatol       Date:  1993-02       Impact factor: 8.551

10.  Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA.

Authors:  B Bouchard; B B Fuller; S Vijayasaradhi; A N Houghton
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  5 in total

1.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

Review 2.  Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

3.  Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.

Authors:  Wolfgang W Leitner; Leroy N Hwang; Michael J deVeer; Aimin Zhou; Robert H Silverman; Bryan R G Williams; Thomas W Dubensky; Han Ying; Nicholas P Restifo
Journal:  Nat Med       Date:  2002-12-23       Impact factor: 53.440

Review 4.  Developing recombinant and synthetic vaccines for the treatment of melanoma.

Authors:  N P Restifo; S A Rosenberg
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

5.  gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Authors:  W W Overwijk; A Tsung; K R Irvine; M R Parkhurst; T J Goletz; K Tsung; M W Carroll; C Liu; B Moss; S A Rosenberg; N P Restifo
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.